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Exploring an increased role for Australian community pharmacy in mental health 




Australian general practitioners primarily treat mental health problems by prescribing 
medication dispensed by community pharmacists. Pharmacists therefore have regular 
interactions with mental health consumers and carers. 
Aims: This narrative review explored the potential role of community pharmacy in mental 
health services. 
Method: Medline, CINAHL, ProQuest, Emerald, PsycINFO, Science Direct, PubMed, Web of 
Knowledge and IPA were utilised. The Cochrane Library as well as grey literature and “lay” 
search engines such as GoogleScholar were also searched. 
Results: Four systematic reviews and ten community pharmacy randomised controlled trials 
were identified. Various relevant reviews outlining the impact of community pharmacy 
based disease state or medicines management services were also identified. 
Conclusion: International studies involving professional service interventions for mental 
health consumers could be contextualised for the Australian setting. Australian studies of 
pharmacy professional services for chronic physical health conditions provided further 
guidance for the expansion of community pharmacy mental health professional services. 
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The management of mental health problems constitutes a significant part of general 
practice (GP) . and data provided by the Australian Institute of Health and Welfare (AIHW) 
estimated that approximately 12.1% of GP encounters in 2011-12 involved a component of 
mental health (Australian Institute of Health and Welfare, 2013). This translates to almost 
15.0 million mental health-related GP encounters annually and the most common 
management option was to prescribe, supply or recommend medication (Australian 
Institute of Health and Welfare, 2013). There were 31.1 million prescriptions dispensed for 
mental health-related medicines subsidised under the Pharmaceutical Benefits Scheme 
(PBS) and the Repatriation Pharmaceutical Benefits Scheme (RPBS) in 2012-13, accounting 
for 11.4% of all prescriptions (Australian Institute of Health and Welfare, 2014). GPs 
generated 86% of prescriptions while psychiatrists and non-psychiatric specialists prescribed 
8% each; the majority of prescriptions were for antidepressant medicines (65.9%) followed 
by anxiolytics (12.2%), antipsychotics (10.6%) and hypnotics and sedatives (8.7%) (Australian 
Institute of Health and Welfare, 2014). 
Prescriptions were dispensed at community pharmacies approved to provide PBS and 
RPBS medicines. Community pharmacists therefore have regular contact with mental health 
consumers and as medication management experts have potential to play an increased role 
in assisting consumers with high prevalence illnesses such as depression and anxiety with 
medication related problems (MRPs). Although the appropriate use of medicines forms an 
integral part of effective management of mental illness, data shows medicines are often 
used sub-optimally (Meagher & Moran, 2003; Mort & Aparasu, 2002). Medication 
adherence to manage mental illness, like most chronic conditions, is an ongoing 
international concern (World Health Organization, 2008; World Health Organization and 




World Organization of Family Doctors, 2008). Regular interaction between community 
pharmacists and mental health consumers provide pharmacists with opportunities to work 
with consumers to address MRPs, facilitate communication with prescribers and other 
members of the healthcare team, and improve medication adherence. 
This narrative review focused on literature reporting professional community pharmacy 
service delivery to improve mental health medication use. It incorporated community 
pharmacy studies in other areas including chronic conditions, those diseases requiring 
lifestyle change and those for which there potentially is stigma attached as recent research 
has highlighted that there is still stigma attached to mental illness despite numerous 
education campaigns (Knox et al., 2014). 
 
The narrative review was undertaken considering that: 
 Mental illness is common in the Australian community with the 2007 National Survey 
of Mental Health and Wellbeing revealing one in five adults had been affected by 
mental illness at some time during the previous 12 months (Australian Bureau of 
Statistics, 2008). 
 In Australia, mild to moderate mental illnesses such as anxiety-related disorders are 
most common (14.4%) followed by mood disorders (6.2%) such as depression 
(Australian Bureau of Statistics, 2008). 
 Government mental health policy supports the management of mild to moderate 
mental illnesses at primary care level (Roxon et al., 2011). 
 Only one third of those with a mental illness used health services for problems with 
their mental health in the previous 12 months (Slade at al., 2009). 




 Community pharmacists are ideally positioned to provide medication management 
support to consumers with mental illness and their carers at primary healthcare level 
(Pharmaceutical Society of Australia, 2013) 
 
METHODS 
A review of the literature was conducted during May to July 2013. Databases utilised 
included Medline, CINAHL, ProQuest, Emerald, PsycINFO, Science Direct, PubMed, Web of 
Knowledge and IPA. The search was limited to English-language studies published in peer-
reviewed journals between January 2002 and December 2012. The search focused on 
systematic reviews about the provision of mental healthcare at primary care level and 
randomised controlled trials in developed countries of mental health services provided by 
pharmacists. Titles and abstracts of articles were scanned and discarded if they did not fit 
the selection criteria. Studies identified as potentially relevant were retrieved and screened 
for relevance. 
The Cochrane Library, Pharmacy Guild of Australia, Pharmaceutical Society of Australia 
and government health sites were also searched as well as “lay” search engines such as 
GoogleScholar. University libraries were explored to access relevant theses if papers had not 
been published in peer-review journals.  
This narrative review involved synthesis and sense-making of the literature as well as an 
interpretation of the studies in the context of professional service delivery in Australian 
community pharmacy. Search terms used were community pharmacy, community 
pharmacist AND mental health, interventions, services, service provision, medicines 
management, adherence, concordance, assessment and skills, attitudes, beliefs, stigma, 








Four systematic reviews investigating the provision of medication management at primary 
care level and ten randomised controlled trials of mental health services provided by 
pharmacists were identified. A number of reviews outlining the impact of community 
pharmacy based disease state or medicines management services were also evaluated as 
well as literature on the Australian community pharmacy setting. 
 
Community pharmacy mental health professional services 
Four systematic reviews were undertaken investigating the role of community 
pharmacy delivering mental healthcare services: 
1. Bell et al. (2005) described pharmacy services to community based mental health 
consumers living at home or in residential care as well as clinical pharmacy services 
to other health professionals. This review provides evidence that pharmacists can 
contribute to optimising the use of medications in the community setting. 
2. Rubio-Valera et al. (2011) focussed on pharmacist interventions to improve 
consumer adherence to antidepressant therapy. The authors suggested that a 
pharmacist intervention is effective in the improvement of consumer adherence to 
antidepressants but acknowledged that data were still limited. 
3. Chong et al. (2011) reviewed 26 studies with interventions that improved both 
adherence and depression outcomes. Several of the studies were in primary care 
settings and the review concluded that educational interventions alone were 




ineffective and that there was evidence for the need for multifaceted interventions 
including educational, behavioural, affective and provider targeted strategies. 
4. Al-Jumah and Qureshi (2012) published a systematic review of the impact of 
pharmacist interventions on consumer adherence to antidepressants and patient-
reported outcomes. The review concluded that pharmacists’ interventions were 
effective in the improvement of adherence to antidepressants. 
 
The systematic reviews largely focussed on improvements in adherence to medication 
and consumer/patient outcomes relating to depressive symptoms. These reviews are 
important as they lay the foundation for understanding what may and may not work for 
mental health consumers provided with medication management services by community 
pharmacists. From these systematic reviews eight RCTs were identified. Another two RCTs 
were added through a further review: (1) a PhD thesis by Harris (2005) from Nottingham 
University describes a pilot RCT of community pharmacists and key workers undertaking 
joint domiciliary visits providing pharmaceutical care and adherence support to older adults 
with mental health problems, and (2) a Spanish study reports on adherence and depression 
outcomes in patients newly initiated on antidepressants (Rubio-Valera et al., 2012). In total, 
ten community pharmacy based mental health RCTs were identified. An overview of these 
studies is provided in Table 1. 
The RCTs and systematic reviews provide valuable lessons to be considered in the 
development of future community pharmacy mental healthcare services. A number of 
themes emerged that could result in service delivery shortcomings namely: focus on 
participants newly initiated on antidepressants; focus on adherence as outcome; focus on 
delivering “information” and/or “education” over behaviour change strategies; and lack of 




focus on collaboration with other health professionals. Each of these is described in more 
detail below. 
 
Focus on participants newly initiated on antidepressants 
The large majority of the community pharmacy-based mental health RCTs involved 
consumers who were newly initiated on antidepressants (Brook et al., 2003; Bultman & 
Svarstad, 2002; Capoccia et al., 2004; Finley et al., 2003; Rickles et al., 2005; Rubio-Valera et 
al., 2012). The first four to six weeks of therapy is a crucial time both from an adherence 
perspective and for monitoring response to therapy (Best Practice Advocacy Centre, 2009). 
However, this period may not be ideal for a medication management intervention that 
requires consumer time and commitment for the following reasons: coping with a new 
diagnosis, acute symptoms of illness, and information overload. Also, mental health 
consumers, like consumers with other chronic conditions, have medication management 
needs throughout their treatment journey and not only when initiated on new medicines. 
Research has indeed highlighted that about 50% of people with long-term conditions are 
not adherent, irrespective of the illness or setting (World Health Organization, 2003). 
Medication management services should therefore target all consumers with chronic 
conditions throughout their journey.  
 
Focus on adherence as outcome 
All of the studies focussed on adherence as the key outcome with indirect measures 
such as pharmacy records or consumer self-reports dominating. However indirect 
measurements lack robust evidence. Additionally, evidence highlights that concordance, 




which involves shared decision making between the consumer and the health professional, 
provides better outcomes (National Institute of Clinical Excellence, 2009). 
There is a scarcity of community pharmacy-based literature around medicine 
concordance and medication management models in mental illness. However, there is 
literature on other pharmacy settings (e.g. hospital outpatient services) and interventions to 
improve medication management and mental health outcomes (Al-Jumah & Qureshi, 2012; 
Bell et al., 2005; Chong et al., 2011; Dolder et al., 2003; Rubio-Valera et al., 2011). Doctor 
and nurse led interventions have also been included in broader systematic reviews 
(Vergouwen et al., 2003). 
Few of the community pharmacy based studies included physical medication aids (e.g. 
blister packaging) and yet they are part of other multifaceted outpatient programs such as 
MedsHelp in the United States (US) (Valenstein et al., 2011) and dose administration aids  
programs in Australia (Pharmacy Guild of Australia, 2013). 
Some of the studies report improvements in clinical outcomes or health-related quality 
of life without significant differences in adherence rates between the control arm and the 
intervention (Capoccia et al., 2004; Rubio-Valera et al., 2012). There is evidence to support 
the notion that clinical improvement may not be mediated through adherence alone (Chong 
et al., 2011; Vergouwen et al., 2003). Disentangling the influence of different interventions 
on various outcomes is also challenging. A better understanding of the mode of action of 
different programs is therefore required.  
 
Focus on delivering “information” and/or “education” over behaviour change strategies 
The word “coaching” is used in several studies (Brook et al., 2003) whilst the majority of 
interventions seem to focus more on educational aspects rather than behavioural 




strategies. There is suggestion that educational activities alone may be ineffective and that 
combinations of educational, behavioural, affective and provider-targeted strategies are 
more likely to improve adherence and clinical outcomes (Chong et al., 2011). Consumer 
education and medication monitoring appear to be the most commonly employed 
pharmacist interventions (Al-Jumah & Qureshi, 2012). Other interventions included 
monitoring and management of adverse events, provision of written or visual information, 
and recommendation or implementation of changes or adjustments in medication (Rubio-
Valera et al., 2011). 
Educational strategies included information provision largely in oral and written formats 
but also by telephone and mail (Al-Saffar et al., 2005; Rickles et al., 2005). Behavioural 
strategies included telephone follow-up and monitoring, scheduled pharmacy clinic visits, 
psychotherapy, behavioural prevention plans, and pharmacy refills and checks. Emotional 
and social support were the most commonly adopted affective strategies, with motivational 
interviewing being used in fewer studies (Crockett et al., 2006; Rickles et al., 2005).  
 
Lack of focus on collaboration with other health professionals  
There seems to be little collaboration between pharmacists and the general practice 
team in the community pharmacy based studies and yet this is not the case in models of 
clinical pharmacists working in advanced primary or secondary care settings (Bell et al., 
2005; Chong et al., 2011; Vergouwen et al., 2003). Few assessments were made by other 
healthcare professionals as part of the mental health community pharmacy RCTs whilst in 
some advanced primary care based models, collaborative care is in fact “the intervention” 
(Vergouwen et al., 2003). The collaborative practice approach is not reflected in the 
community pharmacy based RCTs. Provider targeted strategies predominantly included 




feedback on consumer progress to the GP, although it was missing from the majority of 
community pharmacy based interventions. Facilitation of referrals to the mental healthcare 
sector and supervision from specialist psychiatric care were strategies frequently used in the 
wider primary care literature. This highlights the absence of any integration or collaboration 
within the community pharmacy RCTs. 
 
Summary 
There are limited studies exploring professional service interventions for mental health 
consumers in community pharmacy. From the evaluation of the limited literature three 
themes emerged that provide insight into useful strategies in the provision of community 
pharmacy mental health services namely: pharmacist coaching sessions alongside take-
home videos; ongoing monitoring (face-to-face and telephone); and domiciliary visiting 
service. These themes, discussed below, need to be considered in the development of 
future service delivery models. However, the majority of studies in systematic reviews 
relating to medication adherence in mental health were either inpatient (Vergouwen et al., 
2003) or primary care based clinical pharmacy services (Bell et al., 2005; Chong et al., 2011). 
As such, the conclusions from these systematic reviews are not entirely applicable to 
community pharmacy practice. 
A number of strategies for professional service delivery seemed to have worked in 
community pharmacy for mental health consumers. However, there is a dominance of 
reported research from the US with different health systems to Australia. The findings 
therefore need to be contextualised for the Australian setting. Nonetheless the learnings 
from these intervention studies are useful in the development of future Australian 
community pharmacy mental health professional services and are discussed below. 





Pharmacist coaching sessions alongside take-home videos 
Three coaching sessions with the addition of a take home video including illness and 
education-related information improved consumers attitudes to medication and adherence, 
and the intervention consumers were less depressed and less anxious based on a standard 
analysis but not on an intention to treat analysis (Brook et al., 2003). This intervention was 
more effective in consumers with lower levels of education. 
Contrary to these outcomes a similar study in the Netherlands using three education 
sessions and a take-home video found that consumers had no significant difference in 
adherence as measured by electronic pill counter (Bosmans et al., 2007). Further, there 
were no significant differences in depressive symptom scores. The inclusion of a cost-
effectiveness analysis led the authors to conclude that “standard care” should be continued. 
Short duration education sessions (15min first contact and half that for subsequent visits) 
covering both medications and mental illness also demonstrated no statistically significant 
difference in adherence at three and six months nor clinical symptoms or satisfaction with 




Face-to-face medication management monitoring by pharmacists was predictive of 
consumer satisfaction and self-reported adherence for individuals taking antidepressants for 
the first time (Bultman & Svarstad, 2002). One interview focused on how pharmacists 
covered medication history, knowledge, use and beliefs; the second on pharmacist 
monitoring and behaviour. 




Rickles et al. (2005) found that telephone calls by pharmacists to consumers to educate, 
assess, monitor and make recommendations to improve antidepressant adherence resulted 
in significantly improved feedback from consumers. There was a 50% improvement in 
adherence but no statistically significant difference between intervention or control arms in 
terms of either depressive symptomatology or adherence. 
 
Domiciliary visiting service 
A single RCT reported the impact of domiciliary (home) visits by trained community 
pharmacists in conjunction with key workers. Significant improvements in adherence and 
reductions in consumers reporting problems taking medicines were reported (Harris, 2005). 
 
The literature covering professional service interventions for mental health consumers in 
community pharmacy provide valuable insight into aspects that were proven successful and 
less successful. Of interest is that nine of the ten RCTs report on interventions developed for 
depression and no studies reported on more serious mental illnesses (i.e. illness such as 
schizophrenia) requiring antipsychotic treatment. As consumers on antipsychotics would 
similarly benefit from pharmacist services and interventions (i.e. management of adverse 
effects) pharmacists at primary care level could play a critical role in providing care for all 
consumers with mental illness. However, the literature in this area is limited and the review 
was therefore expanded to include non-mental health community pharmacy services. 
 
Community pharmacy non-mental health professional services 
A number of reviews outlining the impact of community pharmacy based disease state 
or medicines management services provide understanding into successful interventions and 




could have some relevance to provision of community pharmacy mental health professional 
services: 
1. Blenkinsopp et al. (2003) undertook a comprehensive overview of the published 
peer-reviewed evidence relating to community pharmacy based activity in the 
reduction of risk behaviours and risk factors for coronary heart disease. RCTs and 
non-randomised experimental studies were identified with positive evaluations in 
the effectiveness of community pharmacy smoking cessation advice. RCTs and 
observational studies were identified for community pharmacy-based lipid 
management. These studies provide evidence of clinical and cost-effectiveness of 
community pharmacy services in smoking cessation and lipid management in the 
prevention and management of heart disease. 
2. Armour et al. (2008) reviewed studies of community pharmacy based disease 
management programs targeting adherence in consumers with asthma, diabetes 
mellitus, and cardiovascular disease. The findings suggested a positive effect on 
clinical outcomes in addition to adherence. A variety of adherence measuring 
methods were used in these studies, ranging from consumer self-report and 
qualitative descriptions to electronic recording. In most cases, strategies to improve 
adherence were part of a complex intervention, and a direct link between the 
intervention and adherence improvement could not be demonstrated. 
3. Blalock et al. (2013) recently suggested that many studies have demonstrated the 
beneficial effects that professional services provided by pharmacists can have on 
consumer health outcomes. From 21 US studies in community pharmacy settings 
information concerning 134 outcomes was extracted. Of these, just over one third 
(37.3%) demonstrated statistically significant, beneficial intervention effects. The 




percentage of studies reporting favourable findings ranged from 50% for blood 
pressure to 0% for lipids, safety outcomes, and quality of life. The authors concluded 
that evidence supporting the effectiveness of pharmacist provided professional 
services delivered in the community pharmacy setting was more limited than in 
other settings. 
 
There appears to be significantly more investigation of professional service delivery 
relating to chronic conditions (such as asthma and cardiovascular disease), and lifestyle 
interventions such as weight management and smoking cessation than for mental health 
conditions. In the Australian context considerable research has been generated in these 
areas with many of the studies funded by the Australian government through the 
Community Pharmacy Agreements (Department of Health, 2014). 
Community pharmacy asthma interventions that involved on-going cycles of 
assessment, goal-setting, monitoring and medication reviews showed improved adherence 
outcomes, significant improvements in symptom control, self-efficacy and quality of life 
(Saini et al., 2007). Recent research supports these findings but also highlights the 
importance of face-to-face contact between the pharmacist and consumer (Bereznicki et al., 
2013). 
A pharmacist delivered health promotion and screening service for cardiovascular 
disease risk factors in a rural community with GP engagement reported community benefit 
through identification and cholesterol testing of at-risk consumers (Hourihan et al., 2003). 
Protocols for improving adherence in hypertensive consumers through comprehensive 
medicines management packages have resulted in increased consumer education (Lau et al., 
2010), detection and referral of high risk cardiovascular disease consumers (Peterson et al,, 




2010). A pilot study outlining a holistic approach to multiple cardiovascular disease risk 
factors reported a significant reduction in risk (McNamara et al., 2012). 
The on-going cycle of assessment, management, monitoring and review provided at 
regular intervals over a six-month period in community pharmacy for diabetic consumers 
demonstrated significant improvements in clinical and humanistic outcomes (Krass et al., 
2007). Community pharmacy based weight management programs involving diet advice, 
behavioural therapy/modification and medication reviews found pharmacies to be 
accessible locations (Kellow, 2011; Reick et al., 2006). However consumers’ opinions about 
the role of community pharmacy in weight management showed that some consumers 
considered pharmacists’ motivations to provide advice related to gaining profit from selling 
a product and expressed concerns about the perceived conflicts of interest as well as lacking 
expertise and time (Um et al., 2012).  
An Australian study that examined pharmacists’ role in smoking cessation considering 
current practice and barriers to service provision found that there was a greater service 
scope for pharmacist involvement in this area (Edwards et al., 2006). In a New Zealand study 
the role of community pharmacists in the provision of opiate substitution therapy (OST) was 
seen as pivotal and integral to addiction treatment (Walters et al., 2012). Although the 
effectiveness of pharmacy based OST is evident and the demand increasing the participation 
rates of community pharmacies varies in the different Australian jurisdictions (Australian 
Institute of Health and Welfare, 2012). Factors influencing non-provider pharmacies have 
been identified as stigma and fear, additional workload, lack of knowledge and absence of 
government sponsored dispensing fees (Department of Health, 2008; Shepherd et al., 2014). 
The findings from the literature of Australian community pharmacists providing 
medication management services to consumers with chronic physical health conditions, that 




require significant lifestyle changes such as smoking cessation or weight management, or 
conditions that have associated stigma such as drug addiction, provide a framework for the 
expansion of community pharmacy mental health professional services. This is particularly 
important as there is a dearth of holistic medication management studies about mental 
health services in the community pharmacy context compared with these other chronic 
diseases and conditions. 
 
Australian community pharmacy setting 
Australian community pharmacy practice has changed throughout the past two decades 
towards a more significant focus on the provision of professional services to improve 
consumers’ medication management. These changes reflect the international move for the 
pharmacy profession to accept an increased medication management responsibility. 
Community pharmacists’ medication management role is important as it has been 
estimated that 190,000 medication-related hospital admissions occur per year in Australia, 
an estimated 2-3% of all admissions with estimated costs in excess of $660million 
(Roughead & Semple, 2009). As community pharmacists have frequent and regular 
interaction with consumers during dispensing of repeat prescriptions and primary 
healthcare advice (Australian Institute of Health and Welfare, 2012) they are in an ideal 
position to provide medication management services, reduce medication related incidents 
and problems, and facilitate medication information transfer during episodes of care. 
Although there is a clear need for community pharmacists to increase medication 
management services, research by Roberts et al. (2008) showed that the lack of 
remuneration for professional services and deficiency in understanding of sustainable 
models of service provision have been barriers to the provision of services. The community 




pharmacy remuneration model has traditionally not included financial compensation for the 
provision of professional services but rather revolved around pharmacists’ dispensing and 
medication supply functions. There has, however, over recent years been a move away from 
the ‘profit-on-medicines’ model through PBS Reforms as medicine is not an ordinary 
commodity of trade (Commonwealth of Australia, 2010). Financial incentives have been 
introduced for the provision of professional services with government-funded remuneration 
to provide medication management services negotiated through the Community Pharmacy 
Agreements (Australian Government, 2010). Professional services currently funded are: 
 Home medicines and residential medication management review services by 
accredited pharmacists, targeted towards older Australians and those using multiple 
medications (Pharmacy Guild of Australia, 2011). 
 In-pharmacy medication review services, referred to as MedsCheck and Diabetes 
MedsCheck, which are reviews of consumers’ medications by pharmacists to 
facilitate consumer discussion to improve medicines use through education, self-
management and medicines adherence strategies to improve health outcomes 
(Department of Health and Ageing & The Pharmacy Guild of Australia, 2012). 
 The Pharmacy Practice Incentive (PPI) program which involves services in six priority 
areas (Pharmacy Guild of Australia, 2012): (1) dose administration aids services for 
consumers who are facing adherence issues; (2) clinical interventions to facilitate the 
recording of recommendations to prescribers for a change in a consumer’s 
medication therapy, means of administration or medication taking behaviour; (3) 
staged supply services to provide medicines in instalments when requested by the 
prescriber; (4) primary healthcare services to provide screening and/or risk 
assessment and disease state management for consumers with diabetes, respiratory 




disease, cardiovascular disease or mental health conditions; (5) community services 
support such as a pharmacy delivery service, mental health first aid training and 
return of unwanted medicines; and (6) working with other healthcare professionals 
to facilitate cooperation, collaboration and better integration of community 
pharmacy into the wider primary healthcare team. 
 
The overall aim of these services is to improve quality use of medicines and reduce 
adverse medicine events and all of these professional services could be utilised to improve 
the medication management of mental health consumers. There has been numerous 
research evaluating the impact of the home medicine review program which has been in 
place since 2001 (Gilbert et al. 2002). The in-pharmacy medication review services and PPIs 
were only introduced in 2010 with data being collected for assessment.  
Community pharmacies participating in Medscheck and Diabetes Medscheck services 
are required to have a screened area or separate room distinct from the general public area 
of the pharmacy. This area could be utilised to provide services to mental health consumers 
given that there may be situations that could be sensitive to discuss and require privacy. 
This is important as a need for increased community pharmacy privacy and confidentiality 
requirements for mental health consumers has been identified as a barrier to utilising 
community pharmacy services (Hattingh et al., 2014). 
Recent research has provided insight into mental health consumers’ experiences of 
community pharmacy. Telephone interviews with 201 mental health consumers and carers 
from three Australian states explored their experiences of community pharmacy services 
(Knox et al., 2014). The results highlighted service gaps as only 36% received verbal advice, 
the majority were not asked whether they experienced side effects, and 60% reported 




rarely or never receiving written medicine information. Despite these shortcomings the 
majority of participants indicated that their expectations were being met and qualitative 
comments showed that consumers value high-quality services that reflected patient-care. 
Semi-structured interviews and focus groups with 74 purposively selected mental health 
consumers and carers highlighted the importance of positive relationships between 
pharmacy staff and consumers to reduce stigma experienced in community pharmacies 
(Knox et al., 2013). The same study found patient-centred care provided by community 
pharmacies promoted mental health consumers’ and carers’ trust in pharmacists and 
promoted relationship development (Mey et al., 2013). The findings from these studies 
provide valuable information about consumers’ experiences and needs and expectations of 




This narrative review identified international studies involving professional service 
interventions for mental health consumers that could be contextualised for the Australian 
setting. Although community pharmacy is ideally placed to provide support to mental health 
consumers, there is a scarcity of literature regarding community pharmacy RCTs in mental 
health professional service delivery. A search found 10 RCTs, largely from the US, the 
majority of which were focused on adherence as the main outcome. Multiple measures 
have been used to assess adherence as well as clinical outcomes, general wellbeing and 
quality of life in these studies. The interventions within these RCTs included both education 
alone and education in conjunction with cognitive and behavioural change strategies. Those 




RCTs identified were conducted with consumers who had recently started on 
antidepressants and collaboration with GPs and other health professionals was largely 
missing. Systematic reviews which explored the impact of various pharmacy models on the 
medication adherence of mental health consumers provide some insight although the 
conclusions drawn may not necessarily relate to the community pharmacy model as most of 
these involved hospital inpatient or primary care clinical pharmacy services.  
There is a dearth of holistic medication management studies involving mental health in 
the community pharmacy context compared with other chronic conditions such as asthma, 
cardiovascular disease, diabetes, obesity/weight management and addiction services for 
smoking cessation and opiate substitution. It therefore seems timely to explore a larger role 
for community pharmacy in mental health service delivery in collaboration with GPs and 
other members of the healthcare team. Newer community pharmacy services provide 
opportunity for funding of medication management services. Various professional pharmacy 
service models have developed over recent years to facilitate consumers’ medication 
management at a primary healthcare level (Moullin et al., 2013). 
Australian community pharmacists are in regular contact with mental health consumers 
and carers through the dispensing of medicines. In addition to dispensing services, 
pharmacists and pharmacy staff members also provide other services to mental health 
consumers such as the provision of general healthcare and lifestyle advice, management of 
minor ailments, medication review services and newer professional services. Pharmacists 
are therefore in an ideal position to play a more significant role in the medication 
management of mental health consumers in partnership with other healthcare 
professionals. 




This review focused on medication management mental health services at primary 
healthcare level and the impact of community pharmacy based disease state management 
services. The strength of this review lies in the review of both published literature identified 
through databases and unpublished (grey) literature to contextualise the review in terms of 
contemporary Australian community pharmacy practice. The combination ensured a 
comprehensive review of topics amidst the lack of research about the role of community 
pharmacists in medication management of mental health consumers. However, as this is a 
narrative rather than a systematic review it is possible that not all studies were 
incorporated. Another limitation of this review is the comparison to non-mental health 
pharmacy services. Although these studies provide some insight mental healthcare is unique 
and pharmacy mental health services will require careful planning.   
 
CONCLUSION 
The literature identified a need for community pharmacy to become more involved in 
the provision of mental health professional services. Information from mental health 
systematic reviews may not be entirely applicable to community pharmacy although the 
studies provide a framework that needs to be contextualised for the Australian community 
pharmacy setting. These include initial face-to-face interactions between pharmacists and 
mental health consumers and carers as well as ongoing monitoring. A number of strategies 
seemed to have worked as professional service interventions in community pharmacy for 
other physical health conditions and in non-mental health areas associated with stigma. 
Learnings from these studies could be tailored for mental health service provision. The 
development of a community pharmacy intervention that focuses on mental health 




professional services should ideally incorporate elements from the mental health reviews as 
well as non-mental health studies that have proven successful. 
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Table 1: Summary of Randomised Controlled Trials 
Title Country 
Study Details  
Findings 
Effects of pharmacist monitoring on patient 
satisfaction with antidepressant medication 
therapy (Bultman & Svarstad, 2002) 
Wisconsin, US 
Intervention: 
newly initiated consumers provided with education and monitoring, two 
consumer interviews, two months apart 
Evaluation: 
perceived/self-reported adherence 
Pharmacist monitoring was predictive of satisfaction 
and adherence for individuals taking antidepressants 
for the first time 
Impact of a collaborative care model on 
depression in a promary care setting: a 




consumers assigned to collaborative care arm were assessed at baseline, 
potential stressors identified and provide with education, regular follow-up 
included telephone  calls and clinic visits 
Evaluation: 
adherence to antidepressant medication therapy calculated according to 
prescription refill records, consumer satisfaction with pharmacists’ services 
A collaborative care model that emphasised the role 
of clinical pharmacists had positive effect on multiple 
consumer aspects 
The impact of a pharmacist intervention on 
6-month outcomes in depressed primary 
care patients (Adler et al., 2003) 
Massachusetts, US 
Intervention: 
consumers with major depression and/or dysthymia received in person and 
telephone consultations with clinical pharmacist 
Evaluation: 
improved antidepressant medicine adherence 
Pharmacist intervention for depressed consumers 
reported improved adherence and management of 
depression 
Randomized trial of pharmacist 
interventions to improve depression care 




pharmacists collaborated with primary care providers to provide 
education, adjustment of doses, management of adverse effects and 
adherence monitoring 
Evaluation 
depression scores, adherence, consumer satisfaction and use of depression-
related health care services 
No statistically significant difference in depression 
symptoms, quality of life, adherence, provider visits or 
consumer satisfaction; frequent pharmacist telephone 
contacts and interventions resulted in improvements 
in depression outcomes 
Impact of coaching by community 
pharmacists on drug attitude of depressive 
primary care patients and acceptability to 
patients: A randomized controlled trial 
(Brook et al., 2003) 
Netherlands 
Intervention: 
in-pharmacy “drug coaching” sessions and a take home video about depression 
Evaluation: 
attitudes to antidepressants,  adherence – electronic pill container and 
depressive symptoms 
Pharmacist coaching evaluated positively; improved 
adherence; decreased depression and anxiety; 
intervention particularly effective in consumers with 
lower levels of education 
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Effect of information leaflets and 
counselling on antisdepressant adherence: 
open randomised controlled trial in a 




treatment groups received a patient information leaflet written in Arabic with 
or without counselling from a clinical pharmacist 
Evaluation: 
improved consumer understanding of therapy, higher rates of clinic 
attendance, improved adherence 
Pharmacist educational intervention evaluated 
positively; improved adherence 
Pharmacist telemonitoring of 
antidepressant use: effects on pharmacist-
patient collaboration (Rickles et al., 2005) 
Wisconsin, US 
Intervention: 
three monthly telephone calls,  assess, monitor and make recommendations to 
improve adherence 
Evaluation: 
adherence, pharmacy records (self-reported), depression symptoms  
Improvement in depression symptoms and 
compliance (non-significant); significantly more 
feedback to pharmacists regarding different aspects of 
antidepressant therapy 
Patient outcomes following an intervention 
involving community pharmacists in the 




pharmacists trained to provide medication education, consumer monitoring  
Evaluation: 
pharmacist surveys and interviews,  consumer adherence self-report, Kessler10 
score, drug attitude index 
Adherence to medication high in both groups; both 
groups improved significantly in well-being; no 
significant change to attitude in  medicine treatment 
Pharmaceutical care and adherence support 
by community pharmacists for older people 
with mental health problems in the 




domiciliary visiting service by trained community pharmacists and key worker 
Evaluation: 
adherence as judged by key worker 
Significant improvements in adherence; reductions in 
discrepancies with medicines; improvement in 
medicines storage 
Evaluation of a pharmacist intervention on 
patients initiating pharmacological 
treatment for depression: A randomized 




consumers newly initiated on antidepressants, training session for 
pharmacists, implementation and data collection guidelines, medication 
education, illness education, monitoring 
Evaluation: 
adherence,  clinical severity of depression, health related quality of life, 
satisfaction with pharmacy care 
No statistical difference in adherence; statistically 
significant in quality of life but not in clinical 
symptoms or satisfaction with the pharmacy service 
 
 
